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INTRODUTION
Among sexually transmitted infections, human pa-pilloma virus (HPV) is one of the most prevalent
diseases, but the immune system may be involved in
controlling the virus, allowing a remission in some ca -
ses. If the virus evades the immune response, the in-
fection persists and the infected cells could transform
into cancer cells1.
Worldwide, the HPV infection prevalence is in the
range of 1.4-44%2,3, this becomes important because of
its association with cervical cancer (CC). In Mexico, it
has been reported a HPV infection prevalence of 37.5%
in pregnant women4 and 4.8 % in women seeking cer-
vical Papanicolaou cytology5.
Due to the progression to cancer, in 2000, in Mexi-
co, an estimated of 6,650 women died of CC6 and in
2008, approximately 5,061 deaths were reported with
a prevalence of 20.5%7.The CC is related to at least 20
genotypes, of the 100 identified for HPV. For example,
in England it has been estimated that 70% of CC ca -
ses are associated with HPV genotypes 16 and 188.
Fortunately, not all women with HPV infection de-
velop a neoplastic process, phenomenon in which the
immune system may be involved. Immunity is the set
of innate and adaptive responses. The first one has dif-
ferent functions that act against pathogens at the mo-
ment of the first contact with them, being this imme-
diate response not specific and without memory9,10,11.
Usually, in the cervix there are dendritic cells (DCs)
and macrophages, typical cells of the innate immune
response. However, in the presence of HPV, the im-
mune system triggers nonspecific responses, such as,
neutrophil chemoattraction and activation of ma -
crophages, natural killer cells (NK), DC and Lange -
rhans cells (LC)12,13. Therefore, the aim of this review
is to describe the innate immunity involvement in HPV
infection.
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HUMAN PAPILLOMA VIRUS
HPV is a virus of the Papillomaviridae family, sized 50
nm. This virus has no envelope and its genome consists
of a double strand DNA, divided into three regions:
the large control region (LCR), the early region (E),
and the late region (L). The LCR contains the pro-
moters and the initiation sites. The E region includes
genes for nonstructural proteins (E1-E7). E1 and E2
are involved in viral replication and transcription, E5
acts in the early stages of infection, E5 plus E6 and E7
have main role in oncogenesis, particularly E6 and E7
which are involved in viral transformation process by
binding to the cell cycle proteins p53 and Rb, respec-
tively, inhibiting apoptosis and allowing the cells to
proliferate without control. It is in these proteins where
the immune system must act to prevent a neoplastic
process. Finally, the L region contains the L1 and L2,
two genes expressed in late stages of infection in dif-




To produce infection, HPV must pass through the skin
and mucous membranes, translocation facilitated if the
tissues are damaged. Mucus is a major barrier due to
its viscosity and substances therein are collaborating
in reducing pathogens16.
Furthermore, the mucosa-associated lymphoid tis-
sue (MALT) consists of several populations of lym-
phoid cells16,17, bearing pattern recognition receptors
(PPR’s) that recognize HPV pathogen-associated
molecular patterns (PAMP’s). Particularly, in high
grade squamous intraepithelial lesions (SIL), it has
been observed that PAMP’s virus interact with PPR’s
inducing the secretion of interferons (IFNs) and 
other cytokines for the activation and recruitment of
DCs and macrophages in MALT17. However, al-
though MALT in the genital mucosa is an important
barrier against the virus infection, HPV has developed
mechanisms to evade this response.
Microbiota
Other important issue in the response against pa -
thogens, is the microbiota present in the cervix and va -
gina, which consists mainly of Lactobacillus acidophilus
or Döderlein bacillus (which maintains vaginal acidi-
ty), Streptococcus, Staphylococcus, Peptococcus, Peptostrep-
tococcus, Bacteroides speciae, Mycoplasma and Candida.
Microbiota is affected by temperature, hormones, pH
and oxygen tension, allowing installation of pathogens
causing bacterial vaginitis, sexually transmitted infec-
tions and cervical lesions. Common microorganisms
associated with these pathologies are: Gardnerella vagi-
nalis, Candida sp, Staphylococcus aureus, and Escherichia
coli. In some cases there is an association of two or more
pathogens18,19,20.
Beyond the above mentioned concepts, it is ac cepted
that people with bacterial vaginosis have increased sus-
ceptibility to viral infections 21. Furthermore, it has been
found that HPV coinfection with Chlamydia tra-
chomatis or Mycoplasma hominis is associated with low-
grade SIL 22,23.
Cell receptors
If physical barriers and microbiota fail to prevent HPV
infection, then the virus, using different receptors,
pene trate epithelial cells and proliferate16. These re-
ceptors are the glycosaminoglycans (GAGs), specifi-
cally hepa ran sulfate proteoglycans (HSPG) found in
the extracellular matrix and the cell surface (Figure 1).
Other receptors reported for HPV internalization are
clathrin, caveolin, tetraspanin and laminin-514,24,25.
a6b1 and a6b4 integrins, expressed on the surface
of basal epithelial cells, have been suggested as sec-
ondary receptors, involved in internalization, preceded
by HSPG recognition14,17,25. However, it has been found
that a6b1 integrin serves as a HPV6 receptor, but is not
necessary for other genotypes24, so that recognition can
be genotype specific.
Due to the fact that human and viral nucleic acids
are structurally similar, it is necessary to get the viral
discrimination between species. This problem is solved
by Toll-like receptors (TLR)26,27, expressed in DC, LC,
macrophages, monocytes, neutrophils and keratino cy -
tes (KCs). Several types of TLRs, such as TLR3,
TLR7, TLR8, and TLR9 are involved in specific viral
recognition in endosomal compartments26. Moreover,
it has been found, on injured cervical stroma, that IFN-
-1 may induce increased expression of TLR’s 1, 3, 5 and
728. Molecules such as myeloid differentiation factor 88
(MyD88), nuclear factor kB (NF-kB) and the family
of interferon regulatory factor (IRF) are necessary to
activate the TLR’s, thereby allowing the activation of
cells that secrete reactive oxygen species (ROS), in-
flammatory cytokines, interferons, and chemokines26.
If infected human KCs express E6 and E7, then the
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TLR9 mRNA decreases, especially if the HPV 16 is
the infecting virus, leading to the infection persis-
tence29.
Keratinocytes
These cells predominate in epithelium; they differen-
tiate from the basal layer to the stratum corneum. Un-
differentiated KCs of the basal layer are targets of vi-
ral infection and expression of viral genes is detectable
only in these cells. The rapid replication of KCs allows
cells to divide, one cell migrates to the next suprabasal
layer and the other is maintained in the basal layer al-
lowing the infection to be continued30,31. In the epithe -
lial dysplasia the KCs exhibit loss of epidermal
differen tiation plus an increment of nuclear polymor-
phisms and cell proliferation. These disorders are
characte rized by changes in the expression of kera -
tins32, deregulation of genes of the components of the
cytoskeleton and extracellular matrix as vimentin, os-
teonectin and fibronectin30.
In the epithelial basal layer, the oxygen partial pres-
sure is low, and the keratinocyte differentiation is hi -
gher when the oxygen increases. In HPV infected basal
cells, E6 produces an increment of ROS concentra-
tion and consequently DNA damage is produced, al-
lowing the integration of HPV and the occurrence of
cancer10.
TLR9 and TLR3 of the KCs recognize HPV acti-
vating NF-kB, resulting in the production of proin-
flammatory cytokines and activation of signaling path-
ways, particularly type I interferons (Figure 1) and
transcription factors IRF7 and IRF333,34. DeCarlo et al
have reported that normal ectocervix KCs express
abundantly TLRs 1, 2, 3, 5, and 6 and express low le -
vels of TLRs 4, 7, 8 and 9, while in KCs from pre-ma-
lignant epithelium, TLR3 is highly expressed and
TLR1 is expressed at low levels. In epithelial carcino-
ma, RTTs receptors are decreased except TLR828.
In addition, KCs also have antimicrobial defensins,
involved in the innate response31. The a-defensins (a
group of arginine and cysteine-rich antimicrobial
pepti des) are innate compounds effective in inhibiting
HPV infection in humans and are expressed in
leukocy tes and epithelial tissue. It has been observed
high concentration of defensin HD-5 in differentia ted
KCs in various genitourinary sites of the woman, and
the testicles and the urethra in men. This defensin
could be absent in KCs that become the target of HPV
infection. It has been suggested that women who ex-
press high levels of a-defensins may be resistant to ini-
tial infection and persistence of HPV, also, this de-
fensin has a postcoital microbicide property, proving a
natural barrier to the sexual transmission of HPV35.
Dendritic cells (DCs)
The DCs represent a group of antigen-presenting cells
involved as a link between the innate and adaptive res -
ponse. They can be classified into myeloid and plas-
macytoid lineages. The former has two types: the in-
terstitial cells (ICs) which are found in peripheral tis-
sues and in the dermis and LCs, located in the epithe-
lium where they express TLR4. The plasmacytoid
lineage cells (PDCs) are found into lymphoid organs
and abnormal skin, expressing TLR7 and TLR9. The
PDCs can be activated through TLR9, by CpG do-
mains of HPV, allowing the production of high levels
of IFN-a and stimulation of macrophages and NK36.
Other activation pathway is through TLR2/TLR6,
which regulates IL-10 and TGF-b secretion, instead
of pro-inflammatory cytokines (IL-6, IL-12 or TNF-
-a)27. Furthermore, LCs called “immature DC”, are
specialized cells that reside in the cervical epithelium37.
After HPV recognition by LCs, signaling cascades are
activated by mitogen-activated protein kinases
(MAPK), NF-kB, phosphatidylinositol 3-kinases
(P13-K), and Protein Kinase B (PKB). These proteins
play a crucial role in regulating multiple signaling
FIGURE 1. HPV infection model and activation of the innate 
immune response. NK (natural Killer), DC (Dendritic Cell),
HPV (Human Papilloma Virus), HSPG (heparin sulfate 
proteoglycans), TLRs (Toll like receptors). The HPV virus is 
recognized first by the HSPG receptor and then by the secondary
receiver integrin, finally its DNA is released, being recognized by
TLRs in the endosomes, leading to IFNs production and NF-κB
stimulation along the production of cytokines, activating the 
innate immune cells such (macrophages, NK and DC)
channels of viral clearance38. It is well known that Th1,
NK and DCs cells produce IFN-gwhich could activate
DCs and NK cells receptors triggering antiviral ef-
fect39,40.
Macrophages
As well as dendritic cells (DCs), macrophages are anti-
gen presenting cells involved as the link between the
innate and the adaptive response. Tumor associated
macrophages (TAM) are important components of
precancerous lesions and cancer caused by HPV, with
direct effects on the growth, vascularization and modu -
lation in the tumors of stroma41,42.
There are two types of macrophages: type 1 (M1)
and type 2 (M2). M1 are characterized for the pro-
duction of inducible nitric oxide synthase (iNOS),
ROS, and IL-12. This cytokine stimulates the pro-
duction of Th1 and NK cells. M1 can phagocyte HPV,
and are predominantly found in HPV infected tissue
and squamous intraepithelial lesions (SIL). M2 may
develop in response to IL-4 or IL-1343, they are found
predominantly in cancer41.
In CC, the increased number of macrophages cor-
relates with disease progression and bad prognosis.
Some authors have shown that macrophages incre-
ment in SIL is correlated with progression to invasive
cancer, both in the epithelium and cervical stroma, be-
ing the largest macrophage infiltration in persistent
SIL. Specifically CD68+ macrophages are associated
with invasive cervical carcinogenesis41-43. 
Two more points are important. First, CC cells also
express macrophage attractants, including colony
stimu lating factor (CSF-1) then serum levels of 
CSF-1 are increased in patients with HPV infection
and SIL42. Second, the macrophages phagocytize, in
vitro, the C33A and C114 human tumor cell lines that
express the HPV 16 E6 protein. In turn, these lines
are not capable of activating the perforin secretion of
NK cells44.
Natural Killer cells
NK are cells of lymphoid origin, involved in defense
against infected cells and are essential components of
innate immunity against viruses that respond via direct
destruction and inflammatory cytokine secretion9. Vi-
ral infection stimulates the production of IFNs by
macrophages and DCs that are responsible for the ac-
tivation of NK cells, which in turn performs lysis of
infected cells. These cells can activate themselves and
other cells of the adaptive immune system45. Cell lines
of human epithelium infected with HPV and low-
grade SIL tissue are resistant to cytolytic activity of
NK cells41,46.
A variant of NK cells expressing the T cell receptor
(TCR), named NKT cells recognize CD1d, a glyco-
protein of the major histocompatibility complex class
1 (MHC-I) that presents lipid antigens. The HPV E5
protein is associated with low expression levels of
CD1d on the surface of virus-infected tissue with high
risk (HPV16) and also with low risk viruses (HPV6);
which can alter the immune response mediated by
CD1d, and thereby avoid destruction by innate im-
munity of the infected cells. While CD1d is hardly ex-
pressed in the cells’ membrane, mRNA levels are not
affected, so that the effect of E5 is at post-transcrip-
tional level. The recognition of CD1d induces the pro-
duction of inflammatory cytokines like IFN-g. Then
CD1d molecule is involved in innate immunity, and
may also serve to activate adaptive immunity47.
Cytokines
Protein molecules are secreted by various cells and act
as regulators of cellular functions, and activators of the
immune system9. Some cytokines (TGF-B, TNF, 
IL-1, IFN type 1 and 2) are in high concentration in
situ and can control the growth of infected cells. In
contrast, when the cytokines are in low concentration
it allows viral persistence, disease progression and ma-
lignant transformation48.
Viral transcription is an important target in the de-
fense mechanisms of innate immunity. The IFN-1 is
a family of cytokines involved in cell proliferation in-
hibition and interference of viral replication and trans -
cription. Within the IFN-1 family, IFN-a, b, Ω, ε, λ
and κ, are found which are the first line of antiviral de-
fense. Within the IFN-2 family, IFN-g is found49,50.
IFNs are capable of activating and attracting immune
cells including neutrophils, macrophages, NK and CD.
However, it has been observed that E6/E7 proteins of
HPV decrease the production of IFNs and molecules
of the IFN signaling pathway. In this pathway parti -
cipates the ISF-3 transcription complex, a mediator of
IFN signaling. This transcription complex is formed by
the association of STAT-1, STAT-2 and p48 proteins.
In presence of E6 protein, there is a decrease of 
IFN-a, IFN-b and STAT-1 mRNA expression33. 
Attached to this, it has been observed that IFN-a not
effectively inhibits E6/E7 transcription in human cer-
vical cell lines. It has been shown that IFN-g is present
in the tissue of those with HPV infection regression.
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Moreover, it has been found that patients with nega-
tive response to IFN-a treatment have high E7 levels1.
There are conflicting studies on the therapeutic ef-
fectiveness of IFNs. Scott (2001) reported that IFN-
-g but not b can inhibit the E6 and E7 transcription
of HPV 16, 18 and 33 in immortalized KCs. In HPV
transformed keratinocyte line (HPK-IA), IFN-b re-
duces the transcription of HPV 16 E6 and E7 genes,
but has no effect on the IFN-g or a48.
The mechanism of inhibition by E7 is unclear. On
the one hand it is known that the HPV E7 protein in-
hibits the IFN-amediated signal transduction. More-
over in vivo studies demonstrate that HPV18 E7 ex-
pression reduces IFN-b by inhibiting the function of
IRF-130. By contrast, another study found that E7,
does not directly affect the IFN pathway, and requires
the coexistence with E6, it means E6/E7 complex is
even more effective than only E633. It has been obser -
ved that E6 might decrease the IL-8 transcription1.
Another important cytokine is IL-2, a central media-
tor in both the innate and adaptive immunity because
it induces the IFN-g secretion produced by NK, NKT,
T helper and cytotoxic T cells47. For other interferons,
it has been reported that the constitutive transcription
of IFN-k, is inhibited in HPV-positive keratinocytes
and it has also been demonstrated that the E6/E7
genes of HPV16, 18, or 31 are sufficient to inhibit
IFN-k transcription51. 
There are several reports on the expression of cy-
tokines. Jayshree in 2009, showed a cytokine profile in
SIL characterized by an increase in the expression of
IL-2R, IL-4, TGF-b and IL-10 and a decrease in the
expression of IL-2 and IFN-g. In a comparative study
of patients with SIL, CC, and normal cervix there were
no differences in IL-1a, IL-6 and TNF-a mRNA ex-
pression levels, while patients with SIL and CC, had
a diminished expression of IFN-g52. In other study 
using the immunofluorescence method, it was obser -
ved that the expression of TNF-a, IFN-g and IL-2 a
was raised in patients with SIL53.
Contradictorily, Scott (2001) found that in women
with HPV infection the IFN-g transcriptional level
was increased, whereas IL-4 expression was de-
creased54. Constitutively, the KCs secrete low levels of
cytokines but they increase the secretion in response to
various stimuli. For example, in HPV transformed
KCs, TGF-b and TNF are increased, which may in-
hibit the growth of HPV immortalized epithelial
cells48. Other diminished genes are PKR and MxA,
2 –5  oligoadenylate synthetase 255, 56,57.
Evasion
The viruses use mechanisms that deregulate the path-
way of antiviral innate immunity, providing, in this
way, their immune evasion and the persistence of the
infection in the host10. The KCs are programmed to
natural cell death in a term of approximately 70 days,
explaining the fact that the infected cells generate no
danger signals, due to lack of exposure to the host im-
mune system. Moreover, in the initial phase of HPV
infection there is no inflammation, since the HPV cy-
cle is lytic with no production of pro-inflammatory
signals that could activate the DCs. Similarly, the HPV
DNA is amplified in small quantities (30-50 copies of
viral DNA per infected cell), so that it cannot be de-
tected by the host immune system and the answer to
the virus does not occur or occurs very late1,13.
During the CC, HPV does not activate DCs by se-
lective mutation of viral L1 protein, thus viral particles
cannot be assembled in large quantities, and are no
longer capable of activating MyD88 of the innate res -
ponse. Low levels of L1 expression are produced in the
upper layers of the epithelium where also the HPV16
L1 protein is unable to activate the LCs. Deletions,
insertions and changes in the open reading frame of
HPV16 L1 result in low L1expression in carcinomas58.
Other form of viral evasion is molecular mimicry,
defined as the process by which the structural proper-
ties of a viral molecule simulate a host molecule. Xe-
roderma pigmentosum group G protein (XPG) and
retinoblastoma binding protein I (RBP-1) are proteins
that protect against tumor formation, the former re-
pairs DNA and the latter suppress tumors. These
molecules have a common domain with E7 protein
HPV16 so that it can escape immune recognition,
probably by inhibiting the function of these proteins or
by competition with them1.
E6 and E7 proteins have significant activity in the
innate immune evasion by HPV. These proteins in-
terfere with the TLR expression, particularly TLR9.
This receptor is inhibited in cells expressing E6 and E7
proteins of HPV1629. The HPV16 E7 protein inhibits
the IFN-  production, being a possible mechanism of
HPV to avoid elimination59 (Figure 2).
CONCLUSION
There are several mechanisms by which the innate im-
mune system can interfere with HPV infection, from
physical barriers such as skin and mucosal cells as well
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as keratinocytes to special cells of the immune system
such as CD, CL and NK, hindering the development
of the disease through the production of IFN or cy-
tokines, either to eliminate the virus or otherwise acti -
vate the adaptive response. Activation of these res -
ponses has been observed in patients where there is a
recovery and no persistence of the disease. Therefore
innate immunity is crucial for the host response, even
deleting the virus or activating the adaptive response
to combat strongly against HPV.
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